Can Auvelity Increase Mania Risk?
Yes, Auvelity (dextromethorphan-bupropion) can precipitate manic, mixed, or hypomanic episodes, particularly in patients with bipolar disorder or risk factors for bipolar disorder, and is explicitly not approved for treating bipolar depression. 1
FDA-Mandated Warning on Mania Risk
The FDA drug label for Auvelity clearly states that antidepressant treatment can precipitate a manic, mixed, or hypomanic episode, with the risk appearing increased in patients with bipolar disorder or who have risk factors for bipolar disorder 1. This is a critical safety consideration that must guide prescribing decisions.
Required Pre-Treatment Screening
Before initiating Auvelity, you must:
- Screen all patients for a personal history of bipolar disorder
- Screen for risk factors including family history of bipolar disorder, suicide, or depression 1
- Recognize that Auvelity is not approved for use in treating bipolar depression 1
The Bupropion Component and Mania Risk
While bupropion has historically been considered to have a "lower" risk of inducing mania compared to other antidepressants, recent evidence challenges this assumption:
Evidence Against the "Lower Risk" Claim
A 2016 meta-analysis found that the rate of phase shifting (switching to mania/hypomania) with bupropion was not significantly different from other antidepressants (P = 0.952) 2. This directly contradicts the traditional belief that bupropion carries less mania risk and should prompt heightened vigilance when prescribing to any patient with bipolar risk factors.
Case Reports Document Real-World Risk
Two case reports from 2019 documented manic shifts in bipolar patients when bupropion was added as an adjunct to mood stabilizer treatment 3:
- A 43-year-old female on lithium and quetiapine developed manic symptoms after bupropion addition
- A 26-year-old male on lithium and valproate developed psychotic mania requiring hospitalization after bupropion addition
- Both cases showed rapid improvement after bupropion discontinuation 3
Clinical Context: Antidepressants and Bipolar Disorder
The broader evidence on antidepressants in bipolar disorder provides important context:
General Antidepressant Risk in Bipolar Disorder
Guidelines emphasize that antidepressants may destabilize mood or incite a manic episode in bipolar patients 4. Critically, antidepressants should only be used as adjuncts when the patient is also taking at least one mood stabilizer 4.
A retrospective review found that 58% of youths with bipolar disorder experienced emergence of manic symptoms after exposure to mood-elevating agents, most often antidepressants 4.
Important Distinction
A manic episode precipitated by an antidepressant is characterized as substance-induced per DSM criteria 4. However, this does not diminish the clinical significance—the patient still experiences a manic episode with all its associated morbidity and potential for harm.
Practical Clinical Algorithm
When Auvelity is Contraindicated:
- Any patient with diagnosed bipolar I or II disorder (Auvelity is not approved for bipolar depression) 1
- Patients with history of antidepressant-induced mania/hypomania
- Patients with strong family history of bipolar disorder without adequate mood stabilizer coverage
If Considering Auvelity in At-Risk Patients:
- Do not prescribe if any bipolar disorder diagnosis exists
- If risk factors present but no diagnosis:
- Complete thorough screening for bipolar spectrum symptoms
- Assess family psychiatric history in detail
- Consider alternative treatments with lower activation risk
- Never use Auvelity as monotherapy in patients with any bipolar risk factors
Monitoring Requirements:
- Educate patients and families about early warning signs of mania: decreased need for sleep, increased energy, racing thoughts, impulsivity, increased goal-directed activity
- Schedule early follow-up (within 1-2 weeks of initiation)
- Discontinue immediately if any manic or hypomanic symptoms emerge 1
Common Pitfall to Avoid
Do not rely on the historical notion that bupropion has a "lower" mania risk. The most recent meta-analysis shows no significant difference in phase-shifting rates compared to other antidepressants 2. This outdated belief may lead to false reassurance and inadequate monitoring.
Additional Safety Considerations
Beyond mania risk, Auvelity carries other neuropsychiatric warnings: